关注
Zhan Yao
Zhan Yao
Loxo oncology at Lilly
在 loxooncology.com 的电子邮件经过验证
标题
引用次数
引用次数
年份
BRAF mutants evade ERK-dependent feedback by different mechanisms that determine their sensitivity to pharmacologic inhibition
Z Yao, NM Torres, A Tao, Y Gao, L Luo, Q Li, E de Stanchina, ...
Cancer cell 28 (3), 370-383, 2015
4772015
Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS
Z Yao, R Yaeger, VS Rodrik-Outmezguine, A Tao, NM Torres, MT Chang, ...
Nature 548 (7666), 234-238, 2017
4752017
Diverse and targetable kinase alterations drive histiocytic neoplasms
EL Diamond, BH Durham, J Haroche, Z Yao, J Ma, SA Parikh, Z Wang, ...
Cancer discovery 6 (2), 154-165, 2016
4652016
Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
VS Rodrik-Outmezguine, M Okaniwa, Z Yao, CJ Novotny, C McWhirter, ...
Nature 534 (7606), 272-276, 2016
4622016
TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer
Z Yao, S Fenoglio, DC Gao, M Camiolo, B Stiles, T Lindsted, ...
Proceedings of the National Academy of Sciences 107 (35), 15535-15540, 2010
4362010
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence
MH Nissan, CA Pratilas, AM Jones, R Ramirez, H Won, C Liu, S Tiwari, ...
Cancer research 74 (8), 2340-2350, 2014
3532014
Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS–ERK signaling
M Will, ACR Qin, W Toy, Z Yao, V Rodrik-Outmezguine, C Schneider, ...
Cancer discovery 4 (3), 334-347, 2014
2022014
RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling
Z Yao, Y Gao, W Su, R Yaeger, J Tao, N Na, Y Zhang, C Zhang, A Rymar, ...
Nature medicine 25 (2), 284-291, 2019
1592019
Allele-specific mechanisms of activation of MEK1 mutants determine their properties
Y Gao, MT Chang, D McKay, N Na, B Zhou, R Yaeger, NM Torres, ...
Cancer discovery 8 (5), 648-661, 2018
1182018
A Braf kinase-inactive mutant induces lung adenocarcinoma
P Nieto, C Ambrogio, L Esteban-Burgos, G Gómez-López, MT Blasco, ...
Nature 548 (7666), 239-243, 2017
1062017
Response to anti-EGFR therapy in patients with BRAF non-V600–mutant metastatic colorectal cancer
R Yaeger, D Kotani, S Mondaca, AR Parikh, H Bando, EE Van Seventer, ...
Clinical Cancer Research 25 (23), 7089-7097, 2019
1032019
Extreme outlier analysis identifies occult mitogen-activated protein kinase pathway mutations in patients with low-grade serous ovarian cancer
RN Grisham, BE Sylvester, H Won, G McDermott, D DeLair, R Ramirez, ...
Journal of Clinical Oncology 33 (34), 4099-4105, 2015
1002015
Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin
J Xu, CG Pham, SK Albanese, Y Dong, T Oyama, CH Lee, ...
The Journal of clinical investigation 126 (9), 3526-3540, 2016
992016
A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas
Y Sun, JA Alberta, C Pilarz, D Calligaris, EJ Chadwick, SH Ramkissoon, ...
Neuro-oncology 19 (6), 774-785, 2017
982017
p53Ψ is a transcriptionally inactive p53 isoform able to reprogram cells toward a metastatic-like state
S Senturk, Z Yao, M Camiolo, B Stiles, T Rathod, AM Walsh, ...
Proceedings of the National Academy of Sciences 111 (32), E3287-E3296, 2014
972014
Mutant-selective degradation by BRAF-targeting PROTACs
S Alabi, S Jaime-Figueroa, Z Yao, Y Gao, J Hines, KTG Samarasinghe, ...
Nature communications 12 (1), 920, 2021
962021
Mechanisms of acquired resistance to BRAF V600E inhibition in colon cancers converge on RAF dimerization and are sensitive to its inhibition
R Yaeger, Z Yao, DM Hyman, JF Hechtman, E Vakiani, HY Zhao, W Su, ...
Cancer research 77 (23), 6513-6523, 2017
752017
A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor
J Wang, Z Yao, P Jonsson, AN Allen, ACR Qin, S Uddin, IJ Dunkel, ...
Cancer discovery 8 (9), 1130-1141, 2018
672018
B23 acts as a nucleolar stress sensor and promotes cell survival through its dynamic interaction with hnRNPU and hnRNPA1
Z Yao, S Duan, D Hou, W Wang, G Wang, Y Liu, L Wen, M Wu
Oncogene 29 (12), 1821-1834, 2010
662010
Phosphorylation of Pirh2 by Calmodulin‐dependent kinase II impairs its ability to ubiquitinate p53
S Duan, Z Yao, D Hou, Z Wu, W Zhu, M Wu
The EMBO journal 26 (13), 3062-3074, 2007
612007
系统目前无法执行此操作,请稍后再试。
文章 1–20